Related Experiment Video
Updated: Mar 7, 2026
Multimodal Study of Murine Cardiovascular Remodeling: Four-Dimensional Ultrasound and Mass Spectrometry Imaging
Published on: January 10, 2025
Nanomedicine applied to cardiovascular diseases: latest developments
Virna Margarita Martín Giménez1, Diego E Kassuha1, Walter Manucha2,3
1Instituto de Investigaciones en Ciencias Químicas, Facultad de Ciencias de la Alimentación, Bioquímicas y Farmacéuticas, Universidad Católica de Cuyo, Sede San Juan, Argentina.
Insights
New nanotechnology and controlled-release drug strategies offer improved treatments for cardiovascular diseases like hypertension and hyperlipidemia, overcoming limitations of traditional therapies.
Area of Science:
- Biomedical Engineering
- Cardiovascular Medicine
- Nanotechnology
Background:
- Cardiovascular diseases (CVDs) are a leading cause of global mortality and disability.
- Current therapeutic options for CVDs often have insufficient efficacy and undesirable side effects.
- There is a critical need for advanced therapeutic strategies to manage CVD progression effectively.
Purpose of the Study:
- To explore novel technological approaches for treating cardiovascular diseases.
- To address the limitations associated with conventional cardiovascular therapies.
- To highlight advances in nanotechnology and controlled drug release for CVD management.
Main Methods:
- Review of recent scientific and technological developments in cardiovascular disease treatment.
- Focus on the application of nanotechnology in drug delivery systems.
- Investigation of controlled-release drug strategies for managing specific CVDs.
Main Results:
- Nanotechnology enables targeted drug delivery, potentially reducing side effects.
- Controlled-release systems offer sustained therapeutic levels, improving treatment efficacy.
- These advanced methods show promise for managing hyperlipidemia, hypertension, myocardial infarction, stroke, and thrombosis.
Conclusions:
- Nanotechnology and controlled drug release represent significant advancements in cardiovascular disease therapeutics.
- These innovative approaches can overcome many limitations of traditional treatments.
- Continued research in these areas is crucial for developing more effective CVD management strategies.
Abstract:
Cardiovascular diseases are a major cause of disability and they are currently responsible for a significant number of deaths in a large percentage of the world population. A large number of therapeutic options have been developed for the management of cardiovascular diseases. However, they are insufficient to stop or significantly reduce the progression of these diseases, and may produce unpleasant side effects. In this situation, the need arises to continue exploring new technologies and strategies in order to overcome the disadvantages and limitations of conventional therapeutic options. Thus, treatment of cardiovascular diseases has become one of the major focuses of scientific and technological development in recent times. More specifically, there have been important advances in the area of nanotechnology and the controlled release of drugs, destined to circumvent many limitations of conventional therapies for the treatment of diseases such as hyperlipidemia, hypertension, myocardial infarction, stroke and thrombosis.
Related Concept Videos
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:27Coronary Artery Disease V: Interprofessional Care
01:16Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...